drug-discovery
Millions of protein complexes added to AlphaFold Database shed light on how proteins interact
Powering drug discovery through AI-ready protein–ligand data
New data initiative accelerates discovery and personalised care for mental health conditions
New platform integrates gene perturbation data
Why clinical trials stop: the role of genetics
We are EMBL: Melanie Schneider on changing career trajectory
MSD joins the Open Targets consortium
AI annotations increase patent data in SureCheMBL
Understanding the mechanisms of enzyme catalysis
Welcome: David Hulcoop
David Hulcoop appointed as Open Targets Director
ProtVar: understanding missense variation in humans
Bioinformatics powers international effort to map gene function
A human interactome to prioritise drug discovery
Machine learning to identify and prioritise drug targets
The Pistoia Alliance and EMBL-EBI announce HELM collaboration for cheminformatics
ChEMBL_19 Released - Now with Crop Protection Data!
Pfizer joins the Open Targets consortium
AI for drug discovery: what’s the hold up?
Digital Science transfers SureChem patent chemistry data to EMBL-EBI
Where do you start when developing a new medicine?
Biogen Joins Pioneering Target Validation Collaboration
Open Targets: new name, new data
A better way to find drug targets
Takeda joins drug target discovery initiative
Celgene joins Open Targets
Classification of pre-clinical data could boost drug research
Sanofi joins Open Targets
Ian Dunham appointed as Open Targets Director
CRISPR offers new insights into critical cancer changes
eQTL Catalogue – a new resource for gene expression and splicing QTLs
BLAST off! Exploring the universe of biochemical reactions
Target Validation Platform launches
The PROTACtable genome – a new route to drug discovery
Using drug screens and CRISPR to make better cancer drugs
Data integration to speed up drug discovery
